BioCentury | Aug 7, 2017
Company News

Vernalis gets another CRL in cough and cold pipeline

...to six reformulated prescription cough and cold products using OralXR+. One of those products, Tuzistra XR (CCP-01...
...chlorpheniramine polistirex in 2015 (see BioCentury Extra, Feb. 10, 2012 & May 1, 2015) . Alex Himes CCP-07 CCP-08 Tuzistra XR Tris...
BioCentury | Aug 21, 2015
Clinical News

Vernalis to partner off pipeline after Phase II miss

...is a preclinical checkpoint kinase 1 (Chk1) inhibitor. Vernalis will focus on the launch of Tuzistra XR...
...from Tris Pharma Inc. (Monmouth Junction, N.J.). Vernalis holds exclusive North American commercial rights to Tuzistra XR...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

...rifaximin to treat IBS-D in adults Vernalis plc (LSE:VER) / Tris Pharma Inc. FDA approves Tuzistra XR...
...company Aerocrine AB and pulmonary therapeutics developer Prosonix Ltd. Also in 2Q, FDA approved Vernalis' Tuzistra XR...
BioCentury | May 11, 2015
Clinical News

Tuzistra XR codeine polistirex/chlorpheniramine polistirex regulatory update

...FDA approved an NDA from Tris for Tuzistra XR for the relief of cough and symptoms associated...
...with upper respiratory allergies or a common cold in adults. Partner Vernalis hopes to launch Tuzistra XR...
...Pharma Inc. , Monmouth Junction, N.J. Vernalis plc (LSE:VER), Winnersh, U.K. Product: Tuzistra XR codeine polistirex/chlorpheniramine polistirex ( CCP-01...
BioCentury | May 2, 2015
Company News

FDA approves Vernalis' Tuzistra XR

...Vernalis plc (LSE:VER) said FDA approved Tuzistra XR to treat cough and common cold symptoms in adults...
...the start of cold season in September. Vernalis obtained exclusive North American commercial rights to Tuzistra XR...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...the company and partner Tris Pharma Inc. said FDA accepted for review an NDA for Tuzistra XR...
BioCentury | Sep 29, 2014
Clinical News

Tuzistra XR regulatory update

...Tris and Vernalis plc (LSE:VER, Winnersh, U.K.) said FDA accepted for review an NDA for Tuzistra XR...
...July 5, 2014). Vernalis hopes to launch Tuzistra XR "ahead of the 2015-16 cough cold season." Tuzistra XR...
...or from previously approved products. Tris Pharma Inc. , Monmouth Junction, N.J. Product: Tuzistra XR ( CCP-01...
BioCentury | Aug 18, 2014
Company News

Tris Pharma, Vernalis Group deal

...triggered last year by Tris’ achievement of proof of concept for the first undisclosed compound, CCP-01...
BioCentury | Jul 14, 2014
Clinical News

Tuzistra XR regulatory update

...Tris submitted an NDA to FDA for Tuzistra XR for the acute treatment of cough and cold...
...up to 6 reformulated prescription cough and cold products using Tris’ OralXR+ extended-release formulation technology. Tuzistra XR...
...2013 & May 5, 2014). Tris Pharma Inc ., Monmouth Junction, N.J. Product: Tuzistra XR ( CCP-01...
BioCentury | May 5, 2014
Company News

Tris Pharma, Vernalis deal

...triggered last year by Tris' achievement of proof of concept for the first undisclosed compound, CCP-01...
...The partners said they are on track to submit an NDA to FDA for CCP-01...
Items per page:
1 - 10 of 11